Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients

被引:0
|
作者
Horesh, Adi [1 ]
Pollack, Rena [1 ,2 ]
Nechushtan, Hovav [1 ,3 ]
Dresner-Pollak, Rivka [1 ,2 ]
Neuman, Tzahi [1 ,4 ]
机构
[1] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[2] Hadassah Hebrew Univ, Med Ctr, Dept Endocrinol & Metab, Jerusalem, Israel
[3] Hadassah Hebrew Univ, Med Ctr, Dept Oncol, Jerusalem, Israel
[4] Hadassah Hebrew Univ, Med Ctr, Dept Pathol, Jerusalem, Israel
关键词
PD-L1; NSCLC; immune checkpoint inhibitors; immune-related adverse events; thyroid; ADVERSE EVENTS; NIVOLUMAB; PEMBROLIZUMAB; ANTIBODIES; TSH; P53;
D O I
10.3389/pore.2023.1610951
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 expression and molecular profile with the development of thyroid IRAEs in NSCLC patients.Methods: Single center, retrospective study including 107 NSCLC patients treated with PD-1/PD-L1 inhibitors from April 2016 to July 2020. All patients were euthyroid at baseline with at least two TSH measurements post-treatment initiation. The primary outcome was the difference in tumor PD-L1 expression in patients who developed any thyroid IRAEs versus those who remained euthyroid. Additional outcomes included development of overt thyroid dysfunction, the association of specific molecular alterations with thyroid IRAEs, and onset of thyroid IRAEs as a function of tumor PD-L1 expression.Results: Overall, 37 (34.6%) patients developed any thyroid dysfunction and 18 (16.8%) developed overt thyroid dysfunction. Tumor PD-L1 staining intensity was not associated with thyroid IRAEs. TP53 mutation was less likely to be associated with any thyroid dysfunction (p < 0.05) and no association was found between EGFR, ROS, ALK or KRAS mutations. There was no association between PD-L1 expression and time to develop thyroid IRAEs.Conclusion: PD-L1 expression is not associated with the development of thyroid dysfunction in advanced NSCLC patients treated with ICIs, suggesting that thyroid IRAEs are unrelated to tumor PD-L1 expression.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Tumour PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced non small cell lung cancer (NSCLC) Patients
    Neuman, T.
    Vainer, G.
    Horesh, A.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S148 - S148
  • [2] Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index
    Pollack, Rena
    Ashash, Amit
    Cahn, Avivit
    Rottenberg, Yakir
    Stern, Hagay
    Dresner-Pollak, Rivka
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (10): : 1 - 8
  • [3] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [4] Overall Survival by IDO1 and PD-L1 Expression in NSCLC Patients Receiving an Immune Checkpoint Inhibitor (ICI)
    Moore, M.
    Hall, R.
    Mcloughlin, E.
    Melson, J.
    Horton, B.
    Mills, A.
    Gentzler, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S738 - S738
  • [5] PD-L1 profiling of circulating tumor cells for immune checkpoint inhibitor therapy in gastroesophageal cancers
    Devhare, Pradip
    Patil, Revati
    Akolkar, Dadasaheb B.
    Patil, Darshana
    Srivastava, Navin
    Fulmali, Pooja
    Patel, Shoeb
    Shejwalkar, Pradyumna
    Datta, Vineet
    Sims, Cynthe
    Srinivasan, Ajay
    Datar, Rajan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [6] Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patients
    Liu, Yuting
    Zugazagoitia, Jon
    Henick, Brian
    Schalper, Kurt A.
    Rimm, David L.
    CANCER RESEARCH, 2019, 79 (13)
  • [7] PD-L1 profiling of circulating tumor cells for immune checkpoint inhibitor therapy in head and neck cancers
    Patil, Revati
    Akolkar, Dadasaheb B.
    Patil, Darshana
    Devhare, Pradip
    Srivastava, Navin
    Fulmali, Pooja
    Patel, Shoeb
    Shejwalkar, Pradyumna
    Datta, Vineet
    Sims, Cynthe
    Srinivasan, Ajay
    Datar, Rajan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [8] Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC
    Kloten, Vera
    Lampignano, Rita
    Krahn, Thomas
    Schlange, Thomas
    CELLS, 2019, 8 (08)
  • [9] Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
    Melosky, B.
    Chu, Q.
    Juergens, R. A.
    Leighl, N.
    Lonescu, D.
    Tsao, M. -S.
    McLeod, D.
    Hirsh, V.
    CANCER TREATMENT REVIEWS, 2018, 65 : 65 - 77
  • [10] PD-L1 Inhibitor-Induced Thyroiditis and Survival
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (02) : 18N - 18N